GlucoTrack shares are trading higher after the company announced that its subsidiary, Lokahi Therapeutics, is advancing a simplified single-injection strategy for its LT-100 program.

Benzinga Newsdesk www.benzinga.com Positive 94.2%

Neg 0% Neu 0% Pos 94.2%

Comments

No comments yet. Be the first!